OraSure Technologies to Host Analyst Day
November 21 2016 - 6:00AM
OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in
point-of-care diagnostic tests and specimen collection devices,
today announced that it will host an Analyst Day meeting on
Tuesday, November 29, 2016 in New York City, New York, at the
NASDAQ MarketSite at Times Square. Presentations by OraSure’s
senior executive team are scheduled to begin at 10:00 a.m. (Eastern
Time) and conclude by 1:00 p.m. (Eastern Time) and will cover
various aspects of the Company’s business, including growth
initiatives and strategic priorities. There will also be a
question and answer session.
Interested parties can access the live webcast
of the presentations by going to OraSure Technologies’ web site,
www.orasure.com, and clicking on the Investor Information
link. A replay of the webcast will be available until,
December 6, 2016 on OraSure Technologies’ web site.
About OraSure Technologies
OraSure Technologies is a leader in the
development, manufacture and distribution of point of care
diagnostic and collection devices and other technologies designed
to detect or diagnose critical medical conditions. Its
first-to-market, innovative products include rapid tests for the
detection of antibodies to HIV and HCV on the OraQuick® platform,
oral fluid sample collection, stabilization and preparation
products for molecular diagnostic applications, and oral fluid
laboratory tests for detecting various drugs of abuse. OraSure's
portfolio of products is sold globally to various clinical
laboratories, hospitals, clinics, community-based organizations and
other public health organizations, research and academic
institutions, distributors, government agencies, physicians'
offices, commercial and industrial entities and consumers. The
Company's products enable healthcare providers to deliver critical
information to patients, empowering them to make decisions to
improve and protect their health. For more information on
OraSure Technologies, please visit www.orasure.com.
Important Information
All statements included or incorporated by
reference in this release and in the presentations and discussions
at the 2016 Analyst Day, other than statements of historical fact,
are forward-looking statements. These forward-looking statements
are based on the Company’s current expectations, estimates and
projections about its industry and business, management’s beliefs,
and certain assumptions made by management, all of which are
subject to change. Forward-looking statements can often be
identified by words such as “anticipates,” “expects,” “intends,”
“plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,”
“will,” “should,” “would,” “could,” “potential,” “continue,”
“ongoing,” similar expressions, and variations or negatives of
these words. These forward-looking statements are not
guarantees of future results and are subject to risks,
uncertainties and assumptions that could cause the Company’s actual
results to differ materially and adversely from those expressed in
any forward-looking statement.
Known and unknown factors that could cause
actual performance or results to be materially different from those
expressed or implied in these statements include, but are not
limited to: ability to market and sell products, whether
through our internal, direct sales force or third parties; ability
to manufacture products in accordance with applicable
specifications, performance standards and quality requirements;
ability to obtain, and timing and cost of obtaining, necessary
regulatory approvals for new products or new indications or
applications for existing products; ability to comply with
applicable regulatory requirements; ability to effectively resolve
warning letters, audit observations and other findings or comments
from the FDA or other regulators; changes in relationships,
including disputes or disagreements, with strategic partners or
other parties and reliance on strategic partners for the
performance of critical activities under collaborative
arrangements; failure of distributors or other customers to meet
purchase forecasts, historic purchase levels or minimum purchase
requirements for the Company’s products; impact of replacing
distributors; inventory levels at distributors and other customers;
ability of the Company to achieve its financial and strategic
objectives and continue to increase its revenues; ability to
identify, complete, integrate and realize the full benefits of
future acquisitions; impact of competitors, competing products and
technology changes; impact of negative economic conditions, high
unemployment levels and poor credit conditions; reduction or
deferral of public funding available to customers; competition from
new or better technology or lower cost products; ability to
develop, commercialize and market new products; market acceptance
of oral fluid testing or other products; changes in market
acceptance of products based on product performance or other
factors, including changes in testing guidelines, algorithms or
other recommendations by the Centers for Disease Control and
Prevention (“CDC”) or other agencies; ability to fund research and
development and other products and operations; ability to obtain
and maintain new or existing product distribution channels;
reliance on sole supply sources for critical products and
components; availability of related products produced by third
parties or products required for use of our products; history of
losses and ability to achieve sustained profitability; ability to
utilize net operating loss carry forwards or other deferred tax
assets; volatility of the Company’s stock price; uncertainty
relating to patent protection and potential patent infringement
claims; uncertainty and costs of litigation relating to patents and
other intellectual property; availability of licenses to patents or
other technology; ability to enter into international manufacturing
agreements; obstacles to international marketing and manufacturing
of products; ability to sell products internationally, including
the impact of changes in international funding sources and testing
algorithms; adverse movements in foreign currency exchange rates;
loss or impairment of sources of capital; ability to meet financial
covenants in credit agreements; ability to attract and retain
qualified personnel; exposure to product liability and other types
of litigation; changes in international, federal or state laws and
regulations; customer consolidations and inventory practices;
equipment failures and ability to obtain needed raw materials and
components; the impact of terrorist attacks and civil unrest; and
general political, business and economic conditions. These
and other factors are discussed more fully in the Company’s
Securities and Exchange Commission filings, including its
registration statements, Annual Report on Form 10-K for the year
ended December 31, 2015, Quarterly Reports on Form 10-Q, and other
filings with the SEC. Although forward-looking statements help to
provide information about future prospects, readers should keep in
mind that forward-looking statements may not be reliable. The
forward-looking statements mentioned above are made as of the date
such statements are made and OraSure Technologies undertakes no
duty to update these statements.
Company Contact:
Ronald H. Spair
Chief Financial Officer
610-882-1820
Investorinfo@orasure.com
www.orasure.com
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Apr 2023 to Apr 2024